PharmaMar inks deal to commercialize Yondelis in Turkey

10 August 2020

Spanish drugmaker PharmaMar (MC: PHM) has entered into a licensing agreement with Onko Ilac San ve Tic to commercialize its marine-derived anticancer drug Yondelis (trabectedin) in Turkey.

Under the terms of the agreement, PharmaMar will receive a non-disclosed upfront payment and will be eligible for additional remunerations, including regulatory milestone payments. PharmaMar will retain exclusive production rights of the product and will sell the product to Onko for its clinical and commercial use.

This new agreement follows PharmaMar's announcement in August 2019, revealing it was re-gaining rights to Yondelis in more than 40 countries that had previously be licensed to Johnson & Johnson (NYSE: JNJ) subsidiary Janssen.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK